Human Recombinant EGF-L7 (from E. coli)

Supplier: PEPROTECH INC.
Ratings: (No Reviews)

Total Ratings: 0
Avg. Ratings: 0.0 out of 5

100-61-2UG 100-61-10UG 100-61-50UG 100-61-100UG 100-61-250UG 100-61-500UG 100-61-1MG
10779-036EA 143.88 USD
10779-036 10779-038 10779-040 10779-042 10779-044 10779-046 10779-048
Human Recombinant EGF-L7 (from E. coli)
Proteins and Peptides

EGF-L7 (Epidermal growth factor-like protein 7, Multiple EGF-like domains protein 7, VE-statin) is a multi-domain protein containing two EGF-like domains and one EMI domain. It is expressed almost exclusively in endothelial cells and functions to promote normal development of the vascular system, particularly tubulogenesis. EGF-L7 is capable of antagonistic binding to Notch receptors, resulting in the inhibition of Notch signaling in HUVEC and neural stem cells. In research models inducing hypoxia and subsequent reoxygenation (H/R), EGF-L7 can inhibit ICAM-1 expression and enhance the inhibition of NF-κB activation. Additionally, EGF-L7 can chemoattract endothelial cells and bind to the extracellular matrix. The overexpression of EGF-L7 is observed in various cancers, and is generally correlated with increased metastasis and a poor prognosis. Recombinant Human EGF-L7 is a 27.4 kDa protein containing 251 amino acid residues.


Ordering information: For research use only. Not for use in diagnostic or therapeutic procedures.

Order Now


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR